Trinity Identifies Value Proposition of Most Expensive Drugs Approved by the FDA from 2014-2016

Trinity today, in tandem with the 22nd Annual International ISPOR Meeting, announced the results of a white paper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the costliest drugs to the healthcare system approved by the FDA from 2014-2016 in order to understand the interaction between value and price.

In this industry analysis, Trinity reveals the factors that appear to allow some drugs a higher price point than others and addresses key questions including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for?

See all Thought Leadership posts